Skip to main content
. 2022 Oct;13(5):2154–2168. doi: 10.21037/jgo-22-929

Figure 1.

Figure 1

miR-375 levels were lower in serum, ESCC tissues, and ESCC cell lines. (A) Survival analysis of miR-375 in ESCC patients from TCGA databases. (B) ESCC tissues and adjacent tissues under the microscope (H&E Staining). (C) TaqMan probe-based RT-qPCR assessment of miR-375 levels in ESCC tissues and corresponding adjacent noncancerous clinical samples. (D) TaqMan probe-based RT-qPCR assessment of miR-375 levels in serum with ESCC and healthy volunteers. (E) The relative levels of miR-375 in TE-1, ECA-109, and TE-10 ESCC cells, and the non-malignant cancer cell line, Het-1A, were examined by RT-qPCR. Data are presented as the mean ± SD of three independent experiments. *P<0.05. **P<0.01. ESCC, esophageal squamous cell carcinoma; RT-qPCR, real-time quantitative polymerase chain reaction.